Adecoagro, the Luxembourg-incorporated agribusiness with its operating roots in Argentina, Brazil and Uruguay, has spent the past year reshaping itself. In December it closed the deal that defines the current chapter: a roughly $1.2 billion consolidation of Profertil, Argentina's main nitrogen-fertilizer producer, whose Bahia Blanca urea complex it now controls after buying out both partners. The second quarter was the first clear test of whether that bet was worth making, and the answer so far is decisive. Adjusted EBITDA rose 52% year over year to $172.5 million in the quarter and $258.3 million across the first half, and the Fertilizers segment - roughly flat a year ago because the asset was not yet consolidated - contributed $121.2 million of the second-quarter total, more than double its pro forma year-ago profit.
The flip side is that the new engine runs on a commodity price that is already off its peak. Urea averaged $699 a ton in the quarter, up 57% year over year, after the Middle East conflict (a region that accounts for roughly 30% of global urea trade) pushed spot prices near $800 a ton in April. By the date of the report that spot quote had fallen back to about $480. The legacy businesses were roughly flat to down - sugar and ethanol adjusted EBITDA fell 22%, and the renamed Food & Agriculture segment was anemic at $4.9 million of adjusted EBITDA in the quarter. What happened: the headline growth is almost entirely the fertilizer pivot, and its near-term trajectory depends on a geopolitical spike normalizing. What it means: the fundamental question for investors is no longer whether the Profertil deal was well-executed - it was - but whether Adecoagro can keep generating this kind of cash once urea prices settle, while it carries $1.69 billion of net debt (3.0x trailing twelve-month adjusted EBITDA on a pro forma basis, and falling).
The stock, at $9.41, sat roughly 38% below the $15.25 high it printed in late March and just above the $7.13 low it touched in mid-December - which is to say the market has already priced in some cycle normalization that the reported quarter does not yet show. Investors are, in effect, buying a deleveraging story: capex is light inside the quarter, fertilizer sales are seasonally back-loaded, and management says it plans to keep pushing net debt down on higher expected results.